Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy
•HIV-infected children were studied following pneumococcal vaccination on HAART.•Subjects received 2 conjugate (PCV) and 1 polysaccharide (PPV) vaccine doses.•4–5 years later, most had protective antibody concentrations for PCV serotypes.•Antibody responses following a PCV or PPV booster were indica...
Saved in:
| Published in | Vaccine Vol. 31; no. 42; pp. 4782 - 4790 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Kidlington
Elsevier Ltd
01.10.2013
Elsevier Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0264-410X 1873-2518 1873-2518 |
| DOI | 10.1016/j.vaccine.2013.08.002 |
Cover
| Abstract | •HIV-infected children were studied following pneumococcal vaccination on HAART.•Subjects received 2 conjugate (PCV) and 1 polysaccharide (PPV) vaccine doses.•4–5 years later, most had protective antibody concentrations for PCV serotypes.•Antibody responses following a PCV or PPV booster were indicative of memory.•Antibody measured was primarily high avidity antibody.
The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection.
HIV-infected children 2–<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4–5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥0.5mcg/mL of serotype-specific antibody on day 0 or change from <0.5mcg/mL to ≥0.5mcg/mL between day 0 and week 1, or, ≥4-fold antibody rise between day 0 and week 1.
Prior to boosting, 4–5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46mcg/mL (serotype 1), 1.31mcg/mL (serotype 6B), and 1.47mcg/mL (serotype 14), with concentrations ≥0.5mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥0.5mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42–61% for serotype 1 and 87–94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥4-fold antibody rise (serotype 1, 3–13%; serotype 6B, 13–31%; serotype 14, 29–53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5–0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age.
Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4–5 years after PCV7-PCV7-PPV in HIV-infected children on HAART.
Clinical Trials Registration: NCT00257127 (www.clinicaltrials.gov). |
|---|---|
| AbstractList | Background: The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. Methods: HIV-infected children 2-<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4-5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14(PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of greater than or equal to 0.5 mcg/mL of serotype-specific antibody on day 0 or change from <0.5 mcg/mL to greater than or equal to 0.5 mcg/mL between day 0 and week 1, or, greater than or equal to 4-fold antibody rise between day 0 and week 1. Results: Prior to boosting, 4-5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46 mcg/mL (serotype 1), 1.31 mcg/mL (serotype 6B), and 1.47 mcg/mL (serotype 14), with concentrations greater than or equal to 0.5 mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration greater than or equal to 0.5 mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42-61% for serotype 1 and 87-94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 greater than or equal to 4-fold antibody rise (serotype 1, 3-13%; serotype 6B, 13-31%; serotype 14, 29-53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5-0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age. Conclusions: Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4-5 years after PCV7-PCV7-PPV in HIV-infected children on HAART. The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection.BACKGROUNDThe capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection.HIV-infected children 2-<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4-5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥ 0.5 mcg/mL of serotype-specific antibody on day 0 or change from <0.5 mcg/mL to ≥ 0.5 mcg/mL between day 0 and week 1, or, ≥ 4-fold antibody rise between day 0 and week 1.METHODSHIV-infected children 2-<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4-5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥ 0.5 mcg/mL of serotype-specific antibody on day 0 or change from <0.5 mcg/mL to ≥ 0.5 mcg/mL between day 0 and week 1, or, ≥ 4-fold antibody rise between day 0 and week 1.Prior to boosting, 4-5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46 mcg/mL (serotype 1), 1.31 mcg/mL (serotype 6B), and 1.47 mcg/mL (serotype 14), with concentrations ≥ 0.5 mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥ 0.5 mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42-61% for serotype 1 and 87-94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥ 4-fold antibody rise (serotype 1, 3-13%; serotype 6B, 13-31%; serotype 14, 29-53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5-0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age.RESULTSPrior to boosting, 4-5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46 mcg/mL (serotype 1), 1.31 mcg/mL (serotype 6B), and 1.47 mcg/mL (serotype 14), with concentrations ≥ 0.5 mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥ 0.5 mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42-61% for serotype 1 and 87-94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥ 4-fold antibody rise (serotype 1, 3-13%; serotype 6B, 13-31%; serotype 14, 29-53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5-0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age.Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4-5 years after PCV7-PCV7-PPV in HIV-infected children on HAART.CONCLUSIONSProtective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4-5 years after PCV7-PCV7-PPV in HIV-infected children on HAART. Background The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. Methods HIV-infected children 2-<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4-5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of >=0.5mcg/mL of serotype-specific antibody on day 0 or change from <0.5mcg/mL to >=0.5mcg/mL between day 0 and week 1, or, >=4-fold antibody rise between day 0 and week 1. Results Prior to boosting, 4-5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46mcg/mL (serotype 1), 1.31mcg/mL (serotype 6B), and 1.47mcg/mL (serotype 14), with concentrations >=0.5mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration >=0.5mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42-61% for serotype 1 and 87-94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 >=4-fold antibody rise (serotype 1, 3-13%; serotype 6B, 13-31%; serotype 14, 29-53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5-0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age. Conclusions Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4-5 years after PCV7-PCV7-PPV in HIV-infected children on HAART. Clinical Trials Registration:NCT00257127(www.clinicaltrials.gov). The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection.HIV-infected children 2–<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4–5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥0.5mcg/mL of serotype-specific antibody on day 0 or change from <0.5mcg/mL to ≥0.5mcg/mL between day 0 and week 1, or, ≥4-fold antibody rise between day 0 and week 1.Prior to boosting, 4–5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46mcg/mL (serotype 1), 1.31mcg/mL (serotype 6B), and 1.47mcg/mL (serotype 14), with concentrations ≥0.5mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥0.5mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42–61% for serotype 1 and 87–94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥4-fold antibody rise (serotype 1, 3–13%; serotype 6B, 13–31%; serotype 14, 29–53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5–0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age.Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4–5 years after PCV7-PCV7-PPV in HIV-infected children on HAART.Clinical Trials Registration: NCT00257127 (www.clinicaltrials.gov). BACKGROUND: The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. METHODS: HIV-infected children 2–<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4–5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥0.5mcg/mL of serotype-specific antibody on day 0 or change from <0.5mcg/mL to ≥0.5mcg/mL between day 0 and week 1, or, ≥4-fold antibody rise between day 0 and week 1. RESULTS: Prior to boosting, 4–5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46mcg/mL (serotype 1), 1.31mcg/mL (serotype 6B), and 1.47mcg/mL (serotype 14), with concentrations ≥0.5mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥0.5mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42–61% for serotype 1 and 87–94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥4-fold antibody rise (serotype 1, 3–13%; serotype 6B, 13–31%; serotype 14, 29–53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5–0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age. CONCLUSIONS: Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4–5 years after PCV7-PCV7-PPV in HIV-infected children on HAART. Clinical Trials Registration: NCT00257127 (www.clinicaltrials.gov). Highlights • HIV-infected children were studied following pneumococcal vaccination on HAART. • Subjects received 2 conjugate (PCV) and 1 polysaccharide (PPV) vaccine doses. • 4–5 years later, most had protective antibody concentrations for PCV serotypes. • Antibody responses following a PCV or PPV booster were indicative of memory. • Antibody measured was primarily high avidity antibody. •HIV-infected children were studied following pneumococcal vaccination on HAART.•Subjects received 2 conjugate (PCV) and 1 polysaccharide (PPV) vaccine doses.•4–5 years later, most had protective antibody concentrations for PCV serotypes.•Antibody responses following a PCV or PPV booster were indicative of memory.•Antibody measured was primarily high avidity antibody. The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. HIV-infected children 2–<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4–5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥0.5mcg/mL of serotype-specific antibody on day 0 or change from <0.5mcg/mL to ≥0.5mcg/mL between day 0 and week 1, or, ≥4-fold antibody rise between day 0 and week 1. Prior to boosting, 4–5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46mcg/mL (serotype 1), 1.31mcg/mL (serotype 6B), and 1.47mcg/mL (serotype 14), with concentrations ≥0.5mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥0.5mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42–61% for serotype 1 and 87–94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥4-fold antibody rise (serotype 1, 3–13%; serotype 6B, 13–31%; serotype 14, 29–53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5–0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age. Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4–5 years after PCV7-PCV7-PPV in HIV-infected children on HAART. Clinical Trials Registration: NCT00257127 (www.clinicaltrials.gov). The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. HIV-infected children 2-<19 years administered two doses of pneumococcal conjugate vaccine (PCV7) and one dose of polysaccharide vaccine (PPV) on HAART were randomized 4-5 years later to receive a PCV7 or PPV booster. Total and high avidity antibodies to serotypes 1 (PPV) and 6B and 14 (PCV7 and PPV) were determined by ELISA. Memory was defined as persistence of ≥ 0.5 mcg/mL of serotype-specific antibody on day 0 or change from <0.5 mcg/mL to ≥ 0.5 mcg/mL between day 0 and week 1, or, ≥ 4-fold antibody rise between day 0 and week 1. Prior to boosting, 4-5 years after the previous PCV7-PCV7-PPV series, geometric mean concentrations (GMCs) were 0.46 mcg/mL (serotype 1), 1.31 mcg/mL (serotype 6B), and 1.47 mcg/mL (serotype 14), with concentrations ≥ 0.5 mcg/mL in 41% (serotype 1) to 82% (serotypes 6B and 14). Memory based on antibody concentration ≥ 0.5 mcg/mL before or 1 week after boosting with PCV7 or PPV was demonstrated in 42-61% for serotype 1 and 87-94% for serotypes 6B and 14, with lower rates based on day 0 to week 1 ≥ 4-fold antibody rise (serotype 1, 3-13%; serotype 6B, 13-31%; serotype 14, 29-53%). Antibody concentrations post-boosting were greater following PCV7 than PPV for serotypes 6B and 14. Ratios of highly avid to total antibody pre- and post-boosting were 0.5-0.8. Predictors of memory included higher CD4% (nadir before HAART and at P1024 and P1061s entry), CD19% (at P1024 and P1061s entry), and antibody response after the PCV7-PCV7-PPV primary series and lower viral load (at P1024 and P1061s entry) and age. Protective antibody concentrations, high avidity, and booster responses to PCV7 or PPV indicative of memory were present 4-5 years after PCV7-PCV7-PPV in HIV-infected children on HAART. Background: The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. |
| Author | Abzug, Mark J. Nachman, Sharon A. Song, Lin Ye Pelton, Stephen I. Levin, Myron J. Borkowsky, William |
| AuthorAffiliation | a Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO, USA, mark.abzug@childrenscolorado.org b Statistical and Data Analysis Center, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA, song@sdac.harvard.edu c Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO, USA, myron.levin@ucdenver.edu d Department of Pediatrics, State University of New York at Stony Brook, Stony Brook, NY, USA, sharon.nachman@stonybrookmedicine.edu e Department of Pediatrics, New York University School of Medicine and Bellevue Hospital Center, New York, NY, USA, william.borkowsky@nyumc.org f Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA, spelton@bu.edu |
| AuthorAffiliation_xml | – name: d Department of Pediatrics, State University of New York at Stony Brook, Stony Brook, NY, USA, sharon.nachman@stonybrookmedicine.edu – name: f Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA, spelton@bu.edu – name: c Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO, USA, myron.levin@ucdenver.edu – name: b Statistical and Data Analysis Center, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA, song@sdac.harvard.edu – name: e Department of Pediatrics, New York University School of Medicine and Bellevue Hospital Center, New York, NY, USA, william.borkowsky@nyumc.org – name: a Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children’s Hospital Colorado, Aurora, CO, USA, mark.abzug@childrenscolorado.org |
| Author_xml | – sequence: 1 givenname: Mark J. surname: Abzug fullname: Abzug, Mark J. email: mark.abzug@childrenscolorado.org organization: Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA – sequence: 2 givenname: Lin Ye surname: Song fullname: Song, Lin Ye email: song@sdac.harvard.edu organization: Statistical and Data Analysis Center, Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, USA – sequence: 3 givenname: Myron J. surname: Levin fullname: Levin, Myron J. email: myron.levin@ucdenver.edu organization: Department of Pediatrics (Infectious Diseases), University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA – sequence: 4 givenname: Sharon A. surname: Nachman fullname: Nachman, Sharon A. email: sharon.nachman@stonybrookmedicine.edu organization: Department of Pediatrics, State University of New York at Stony Brook, Stony Brook, NY, USA – sequence: 5 givenname: William surname: Borkowsky fullname: Borkowsky, William email: william.borkowsky@nyumc.org organization: Department of Pediatrics, New York University School of Medicine and Bellevue Hospital Center, New York, NY, USA – sequence: 6 givenname: Stephen I. surname: Pelton fullname: Pelton, Stephen I. email: spelton@bu.edu organization: Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27954029$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/23954381$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNU11v0zAUjdAQ-4CfAERCSLy0XMd24ggxNE3AJk3iYQzxZrk3TuuS2MV2K_V38Qdx2o7BJNTlxYp8zrnHR-ceZwfWWZ1lzwmMCZDy7Xy8UojG6nEBhI5BjAGKR9kRERUdFZyIg-wIipKNGIHvh9lxCHMA4JTUT7LDgtacUUGOsl9nNpqJa9b5QvtgQtQWda5sk5u-X1rXuanBvNe98-tctVH7POifS51YqssXVi97hw4x_aCz8-VUxS194bp1SA5nyptG51uzKhpnc2Pzi8tvI2NbjVE3Oc5M13ht83Q3M9NZlyZhNKtBKBqvo3cr49OEONNeLdZPs8et6oJ-tjtPsptPH7-eX4yuvny-PD-7GmHFqziqRcsKRNGgwpJNkJe8FaIsYFLrugSGogUlGKsqaDggA6QtmTBVEK5opTk9yU63uovlpNcNpkcnF3LhTa_8Wjpl5L831szk1K0kFQVPXxJ4sxPwLmUWouxNQN11ymq3DJKUoqwIUEL3QzlAJWrBqv1QVgpaElHXD4BSygmnrEjQV_egc7f0NuWbZvMaasY2L3rxdyR_srgtVAK83gFUSKVovbJowh2uSjgoBmfvtjj0LgSvW4kmbuqRkjSdJCCHmsu53NVcDjWXIGSqeWLze-zbAft4L7e8Vjmppj45u7lOgBQuqWrYhPthi9CpWCujvQxohp1oUhExysaZvTNO7ylgZ6xJYfzQax3uUpWhkCCvhyUddpRQICBKlgTe_1_gAQZ-A-KpUIE |
| CODEN | VACCDE |
| CitedBy_id | crossref_primary_10_1080_21645515_2018_1436424 crossref_primary_10_1080_21645515_2015_1039208 crossref_primary_10_1016_j_vaccine_2016_09_035 crossref_primary_10_1186_s13223_017_0200_2 crossref_primary_10_1586_14760584_2015_1037743 crossref_primary_10_1097_QAI_0000000000001054 crossref_primary_10_1093_infdis_jiy135 crossref_primary_10_1080_21645515_2016_1160987 crossref_primary_10_1016_j_jaci_2014_07_012 crossref_primary_10_7448_IAS_19_1_20631 crossref_primary_10_1097_QAD_0000000000003544 crossref_primary_10_1002_acr_22757 crossref_primary_10_1097_QAD_0000000000000385 crossref_primary_10_1097_QAI_0000000000001000 crossref_primary_10_1097_INF_0000000000000659 crossref_primary_10_1016_j_vaccine_2015_06_077 crossref_primary_10_1097_QAD_0000000000003551 crossref_primary_10_1080_21645515_2015_1098794 |
| Cites_doi | 10.1086/518149 10.1016/S1473-3099(07)70242-6 10.1097/00002030-200306130-00017 10.4049/jimmunol.178.12.8212 10.1097/01.inf.0000237830.33228.c3 10.1182/blood-2005-11-013383 10.1016/j.vaccine.2011.06.072 10.1056/NEJMoa0903029 10.1128/CDLI.12.1.165-170.2005 10.1086/323648 10.4049/jimmunol.180.4.2165 10.1097/QAD.0b013e328341b7f1 10.1016/j.vaccine.2006.09.019 10.1046/j.1365-2249.1999.01077.x 10.1097/QAD.0b013e32828642c7 10.1016/j.vaccine.2011.02.089 10.1086/597388 10.1093/infdis/jis386 10.1128/IAI.67.5.2366-2370.1999 10.1086/597389 10.1016/S0264-410X(01)00347-4 10.1086/653704 10.1016/j.vaccine.2005.06.002 10.1136/adc.88.5.379 10.1016/S1473-3099(07)70210-4 10.1097/01.inf.0000160942.84169.14 10.1093/infdis/jir316 10.7326/0003-4819-144-1-200601030-00004 10.1001/archpedi.1996.02170330064011 10.1086/605448 |
| ContentType | Journal Article |
| Contributor | Courville, Teresa Isaacman, Daniel Jankelevich, Shirley Robbins, Alison Kaul, Aditya Chen, Janet S Kaye, Jean Caporale, Mary Wara, Diane Fenton, Terence Jimenez, Eleanor Smith, Dorothy Keeley, Velma Homans, James Petru, Ann Frere, Maxine Luzuriaga, Katherine Tran, Paul Bonagura, Vincent R Kabat, William Foster, Jill A Davi, Michell Inman, Amy Elkins, Karen Moallem, H Jack Rathore, Mobeen H Handelsman, Edward Angeli, Lourdes Akleh, Siham Maes, Jody Salbenblatt, Carol Tran, Linh Aldrovandi, Grace Paul, Suzanne Hadhazy, Victoria Read, Jennifer Laverty, Susan Gold, Karen Kallury, Anantha Hodge, Janice Pharm, B Melendez, Ana Chandwani, Sulachni Spector, Stephen A Conway, Daniel H Koutsoubis, Gary Jean-Philippe, Patrick Puga, Ann Swindell, Denise Chiu, Thomas Alvarez, Ana Barr, Emily Schuval, Susan J Figueroa, Wanda Murante, Barbra Viani, Rolando Willems, Paul Dummitt, Mavis Yogev, Ram Regan, Ann Marie Stangl, Lisa Mirza, Ayesha Deveikis, Audra Colter, Connie Robinson, Lisa Gaye Gore, Carol Bakshi, Saroj Rosenblatt, Howard M Stuard, Emma Dashefsky, Barry Pursw |
| Contributor_xml | – sequence: 1 givenname: Shirley surname: Jankelevich fullname: Jankelevich, Shirley – sequence: 2 givenname: Patrick surname: Jean-Philippe fullname: Jean-Philippe, Patrick – sequence: 3 givenname: Jennifer surname: Read fullname: Read, Jennifer – sequence: 4 givenname: Victoria surname: Hadhazy fullname: Hadhazy, Victoria – sequence: 5 givenname: Alison surname: Robbins fullname: Robbins, Alison – sequence: 6 givenname: Beth surname: Sheeran fullname: Sheeran, Beth – sequence: 7 givenname: Jane C surname: Lindsey fullname: Lindsey, Jane C – sequence: 8 givenname: Terence surname: Fenton fullname: Fenton, Terence – sequence: 9 givenname: Janice surname: Hodge fullname: Hodge, Janice – sequence: 10 givenname: Mary surname: Caporale fullname: Caporale, Mary – sequence: 11 givenname: Nancy surname: Webb fullname: Webb, Nancy – sequence: 12 givenname: Courtney surname: Ashton fullname: Ashton, Courtney – sequence: 13 givenname: Dorothy surname: Smith fullname: Smith, Dorothy – sequence: 14 givenname: Lourdes surname: Angeli fullname: Angeli, Lourdes – sequence: 15 givenname: John surname: Pella fullname: Pella, John – sequence: 16 givenname: Paul surname: Tran fullname: Tran, Paul – sequence: 17 givenname: Howard M surname: Rosenblatt fullname: Rosenblatt, Howard M – sequence: 18 givenname: Grace surname: Aldrovandi fullname: Aldrovandi, Grace – sequence: 19 givenname: Rachel surname: Barrett fullname: Barrett, Rachel – sequence: 20 givenname: William surname: Kabat fullname: Kabat, William – sequence: 21 givenname: Alan surname: Shaw fullname: Shaw, Alan – sequence: 22 givenname: Daniel surname: Isaacman fullname: Isaacman, Daniel – sequence: 23 givenname: Velma surname: Keeley fullname: Keeley, Velma – sequence: 24 givenname: Paul surname: Willems fullname: Willems, Paul – sequence: 25 givenname: Carol surname: Gore fullname: Gore, Carol – sequence: 26 givenname: Ram surname: Yogev fullname: Yogev, Ram – sequence: 27 givenname: Barry surname: Dashefsky fullname: Dashefsky, Barry – sequence: 28 givenname: Linda surname: Bettica fullname: Bettica, Linda – sequence: 29 givenname: Paul surname: Palumbo fullname: Palumbo, Paul – sequence: 30 givenname: Elaine surname: Abrams fullname: Abrams, Elaine – sequence: 31 givenname: Maxine surname: Frere fullname: Frere, Maxine – sequence: 32 givenname: Lisa Gaye surname: Robinson fullname: Robinson, Lisa Gaye – sequence: 33 givenname: Mahrukh surname: Bamji fullname: Bamji, Mahrukh – sequence: 34 givenname: Audra surname: Deveikis fullname: Deveikis, Audra – sequence: 35 givenname: Susan surname: Marks fullname: Marks, Susan – sequence: 36 givenname: Karen surname: Elkins fullname: Elkins, Karen – sequence: 37 givenname: Lisa surname: Melton fullname: Melton, Lisa – sequence: 38 givenname: Eleanor surname: Jimenez fullname: Jimenez, Eleanor – sequence: 39 givenname: James surname: Homans fullname: Homans, James – sequence: 40 givenname: Ana surname: Melendez fullname: Melendez, Ana – sequence: 41 givenname: Andrea surname: Kovacs fullname: Kovacs, Andrea – sequence: 42 givenname: Mobeen H surname: Rathore fullname: Rathore, Mobeen H – sequence: 43 givenname: Ana surname: Alvarez fullname: Alvarez, Ana – sequence: 44 givenname: Ayesha surname: Mirza fullname: Mirza, Ayesha – sequence: 45 givenname: Thomas surname: Chiu fullname: Chiu, Thomas – sequence: 46 givenname: Stephen A surname: Spector fullname: Spector, Stephen A – sequence: 47 givenname: Rolando surname: Viani fullname: Viani, Rolando – sequence: 48 givenname: Mary surname: Caffery fullname: Caffery, Mary – sequence: 49 givenname: Lisa surname: Stangl fullname: Stangl, Lisa – sequence: 50 givenname: Denise surname: Ferraro fullname: Ferraro, Denise – sequence: 51 givenname: Silvia surname: Muniz fullname: Muniz, Silvia – sequence: 52 givenname: Michell surname: Davi fullname: Davi, Michell – sequence: 53 givenname: Jody surname: Maes fullname: Maes, Jody – sequence: 54 givenname: Carol surname: Salbenblatt fullname: Salbenblatt, Carol – sequence: 55 givenname: Suzanne surname: Paul fullname: Paul, Suzanne – sequence: 56 givenname: Emily surname: Barr fullname: Barr, Emily – sequence: 57 givenname: Vincent R surname: Bonagura fullname: Bonagura, Vincent R – sequence: 58 givenname: Susan J surname: Schuval fullname: Schuval, Susan J – sequence: 59 givenname: Connie surname: Colter fullname: Colter, Connie – sequence: 60 givenname: Ann surname: Petru fullname: Petru, Ann – sequence: 61 givenname: Teresa surname: Courville fullname: Courville, Teresa – sequence: 62 givenname: Karen surname: Gold fullname: Gold, Karen – sequence: 63 givenname: Lauren surname: Poole fullname: Poole, Lauren – sequence: 64 givenname: Janet S surname: Chen fullname: Chen, Janet S – sequence: 65 givenname: Jill A surname: Foster fullname: Foster, Jill A – sequence: 66 givenname: Daniel H surname: Conway fullname: Conway, Daniel H – sequence: 67 givenname: Gary surname: Koutsoubis fullname: Koutsoubis, Gary – sequence: 68 givenname: Ann Marie surname: Regan fullname: Regan, Ann Marie – sequence: 69 givenname: H Jack surname: Moallem fullname: Moallem, H Jack – sequence: 70 givenname: Edward surname: Handelsman fullname: Handelsman, Edward – sequence: 71 givenname: Denise surname: Swindell fullname: Swindell, Denise – sequence: 72 givenname: Jean surname: Kaye fullname: Kaye, Jean – sequence: 73 givenname: Wanda surname: Figueroa fullname: Figueroa, Wanda – sequence: 74 givenname: Mavis surname: Dummitt fullname: Dummitt, Mavis – sequence: 75 givenname: Anantha surname: Kallury fullname: Kallury, Anantha – sequence: 76 givenname: B surname: Pharm fullname: Pharm, B – sequence: 77 givenname: Murli surname: Purswani fullname: Purswani, Murli – sequence: 78 givenname: Saroj surname: Bakshi fullname: Bakshi, Saroj – sequence: 79 givenname: Emma surname: Stuard fullname: Stuard, Emma – sequence: 80 givenname: Steven surname: Arpadi fullname: Arpadi, Steven – sequence: 81 givenname: Katherine surname: Luzuriaga fullname: Luzuriaga, Katherine – sequence: 82 givenname: Dottie surname: Smith fullname: Smith, Dottie – sequence: 83 givenname: Sandra surname: Burchett fullname: Burchett, Sandra – sequence: 84 givenname: Lynne surname: Lewis fullname: Lewis, Lynne – sequence: 85 givenname: Catherine surname: Kneut fullname: Kneut, Catherine – sequence: 86 givenname: Amy surname: Inman fullname: Inman, Amy – sequence: 87 givenname: Linh surname: Tran fullname: Tran, Linh – sequence: 88 givenname: Guillermo surname: Talero fullname: Talero, Guillermo – sequence: 89 givenname: Ann surname: Puga fullname: Puga, Ann – sequence: 90 givenname: John surname: Farley fullname: Farley, John – sequence: 91 givenname: Mary surname: MacFadden fullname: MacFadden, Mary – sequence: 92 givenname: Diane surname: Wara fullname: Wara, Diane – sequence: 93 givenname: Siham surname: Akleh fullname: Akleh, Siham – sequence: 94 givenname: Aditya surname: Kaul fullname: Kaul, Aditya – sequence: 95 givenname: Sulachni surname: Chandwani fullname: Chandwani, Sulachni – sequence: 96 givenname: Thomas surname: Hastings fullname: Hastings, Thomas – sequence: 97 givenname: Geoffrey A surname: Weinberg fullname: Weinberg, Geoffrey A – sequence: 98 givenname: Susan surname: Laverty fullname: Laverty, Susan – sequence: 99 givenname: Barbra surname: Murante fullname: Murante, Barbra – sequence: 100 givenname: Francis surname: Gigliotti fullname: Gigliotti, Francis |
| Copyright | 2013 Elsevier Ltd Elsevier Ltd 2015 INIST-CNRS Copyright © 2013 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Oct 1, 2013 2013 Elsevier Ltd. All rights reserved. 2013 |
| Copyright_xml | – notice: 2013 Elsevier Ltd – notice: Elsevier Ltd – notice: 2015 INIST-CNRS – notice: Copyright © 2013 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Oct 1, 2013 – notice: 2013 Elsevier Ltd. All rights reserved. 2013 |
| CorporateAuthor | for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams |
| CorporateAuthor_xml | – name: for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams – name: International Maternal Pediatric Adolescent AIDS Clinical Trials Group P1024 and P1061s Protocol Teams |
| DBID | FBQ AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T2 7T5 7U9 7X7 7XB 88C 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M0T M1P M2O M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
| DOI | 10.1016/j.vaccine.2013.08.002 |
| DatabaseName | AGRIS CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Health and Safety Science Abstracts (Full archive) Immunology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Journals ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials - QC Biological Science Collection ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database (Alumni Edition) ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Healthcare Administration Database Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Research Library Prep ProQuest Central Student ProQuest Central Essentials SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library Health & Safety Science Abstracts ProQuest Public Health ProQuest Central Basic ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic Research Library Prep AGRICOLA MEDLINE AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database – sequence: 4 dbid: FBQ name: AGRIS url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN sourceTypes: Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Veterinary Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1873-2518 |
| EndPage | 4790 |
| ExternalDocumentID | PMC3825555 3420826181 23954381 27954029 10_1016_j_vaccine_2013_08_002 US201500179047 S0264410X13010864 1_s2_0_S0264410X13010864 |
| Genre | Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: U01 AI068616 – fundername: NIDDK NIH HHS grantid: HHSN267200800001C – fundername: NIAID NIH HHS grantid: UM1 AI106716 – fundername: NCRR NIH HHS grantid: MO1-RR00069 – fundername: NCRR NIH HHS grantid: M01 RR000069 – fundername: NIAID NIH HHS grantid: U01 AI068632 – fundername: NIAID NIH HHS grantid: UM1 AI068632 – fundername: NICHD NIH HHS grantid: HHSN267200800001C – fundername: NIAID NIH HHS grantid: UM1 AI068616 – fundername: NIAID NIH HHS grantid: U01 AI041110 – fundername: National Institute of Child Health & Human Development : NICHD grantid: HHSN267200800001C || HD – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U01 AI068616 || AI – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U01 AI041110 || AI – fundername: National Institute of Allergy and Infectious Diseases Extramural Activities : NIAID grantid: U01 AI068632 || AI |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 123 1B1 1P~ 1RT 1~. 1~5 4.4 457 4G. 53G 5RE 5VS 7-5 71M 7RV 7X7 88E 8AO 8C1 8FE 8FH 8FI 8FJ 8G5 8P~ 9JM AAAJQ AABNK AAEDT AAEDW AAHBH AAIKJ AAKOC AALRI AAOAW AAQFI AARKO AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABFRF ABJNI ABKYH ABMAC ABMZM ABRWV ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACIEU ACIUM ACPRK ACRLP ACVFH ADBBV ADCNI ADEZE ADFRT AEBSH AEFWE AEIPS AEKER AENEX AEUPX AEUYN AEVXI AEXOQ AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGCQF AGEKW AGGSO AGUBO AGYEJ AHMBA AIEXJ AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX AQUVI AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKNYI BKOJK BLXMC BNPGV BPHCQ BVXVI CCPQU CJTIS CNWQP CS3 DWQXO EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K9- KOM L7B LK8 LUGTX LW9 M0R M0T M1P M29 M2O M41 M7P MO0 N9A NAPCQ O-L O9- O9~ OAUVE OK0 OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO Q38 ROL RPZ SAB SCC SDF SDG SDP SES SNL SPCBC SSH SSI SSZ T5K UKHRP UV1 WH7 WOW Z5R ~G- .GJ 29Q 3V. AACTN AAQXK ACRPL ADMUD ADNMO ADVLN AFCTW AFJKZ AFKWA AGHFR AHHHB AJOXV ALIPV AMFUW ASPBG AVWKF AZFZN FEDTE FGOYB G-2 HEJ HLV HMG HMK HMO HVGLF HX~ HZ~ R2- RIG SAE SEW SIN SVS WUQ XPP ZGI ZXP AAIAV ABLVK ABYKQ AESVU AJBFU EFLBG LCYCR QYZTP FBQ AAYXX ACMHX ADSLC AGQPQ AGRNS AGWPP AIGII APXCP CITATION IQODW CGR CUY CVF ECM EIF NPM 7QL 7T2 7T5 7U9 7XB 8FK C1K H94 K9. M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 7S9 L.6 5PM |
| ID | FETCH-LOGICAL-c757t-98f42cc8dcac64bc565f88620b9e9604c8f0a844770d50c40c3f1b4a215a37e53 |
| IEDL.DBID | AIKHN |
| ISSN | 0264-410X 1873-2518 |
| IngestDate | Thu Aug 21 13:35:34 EDT 2025 Thu Sep 04 23:38:22 EDT 2025 Thu Sep 04 15:53:39 EDT 2025 Fri Sep 05 03:51:17 EDT 2025 Thu Sep 04 20:56:52 EDT 2025 Wed Aug 13 06:01:26 EDT 2025 Mon Jul 21 06:05:14 EDT 2025 Wed Apr 02 07:37:53 EDT 2025 Tue Jul 01 03:38:05 EDT 2025 Thu Apr 24 22:58:28 EDT 2025 Thu Apr 03 09:45:52 EDT 2025 Fri Feb 23 02:26:56 EST 2024 Sun Feb 23 10:19:37 EST 2025 Tue Aug 26 16:33:26 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 42 |
| Keywords | Pneumococcal PCV HIV Memory VL PPV Vaccine Children viral load pneumococcal polysaccharide vaccine pneumococcal conjugate vaccine Human Immunopathology Antibody Vaccination Retroviridae AIDS Immune deficiency Lentivirus Streptococcus pneumoniae Infection Virus Streptococcaceae Viral disease Bacteria Micrococcales Antiviral Human immunodeficiency virus Child Polysaccharide |
| Language | English |
| License | CC BY 4.0 Copyright © 2013 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c757t-98f42cc8dcac64bc565f88620b9e9604c8f0a844770d50c40c3f1b4a215a37e53 |
| Notes | http://dx.doi.org/10.1016/j.vaccine.2013.08.002 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | http://doi.org/10.1016/j.vaccine.2013.08.002 |
| PMID | 23954381 |
| PQID | 1559094455 |
| PQPubID | 23462 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3825555 proquest_miscellaneous_1686710313 proquest_miscellaneous_1500789847 proquest_miscellaneous_1468361899 proquest_miscellaneous_1433515342 proquest_journals_1559094455 pubmed_primary_23954381 pascalfrancis_primary_27954029 crossref_citationtrail_10_1016_j_vaccine_2013_08_002 crossref_primary_10_1016_j_vaccine_2013_08_002 fao_agris_US201500179047 elsevier_sciencedirect_doi_10_1016_j_vaccine_2013_08_002 elsevier_clinicalkeyesjournals_1_s2_0_S0264410X13010864 elsevier_clinicalkey_doi_10_1016_j_vaccine_2013_08_002 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2013-10-01 |
| PublicationDateYYYYMMDD | 2013-10-01 |
| PublicationDate_xml | – month: 10 year: 2013 text: 2013-10-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Kidlington |
| PublicationPlace_xml | – name: Kidlington – name: Netherlands |
| PublicationTitle | Vaccine |
| PublicationTitleAlternate | Vaccine |
| PublicationYear | 2013 |
| Publisher | Elsevier Ltd Elsevier Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier – name: Elsevier Limited |
| References | O’Brien, Hochmann, Goldblatt (bib0090) 2007; 7 Spoulou, Tsoumas, Papaevangelou, Mostrou, Theodoridou (bib0110) 2005; 23 Albrich, Baughman, Schmotzer, Farley (bib0015) 2007; 44 Rutstein, Rudy, Cnaan (bib0125) 1996; 150 Hart, Steel, Clark, Moyle, Nelson, Henderson (bib0135) 2007; 178 D’Orsogna, Krueger, McKinnon, French (bib0145) 2007; 21 Iwajomo, Finn, Moons, Nkhata, Sepako, Ogunniyi (bib0150) 2011; 204 Madhi, Adrian, Cotton, McIntyre, Jean-Philippe, Meadows (bib0155) 2010; 202 Titanji, de Milito, Cagigi, Thorstensson, Grützmeier, Atlas (bib0140) 2006; 108 Nunes, von Gottberg, de Gouveia, Cohen, Moore, Klugman (bib0020) 2011; 25 Antttila, Voutilainen, Jantti, Eskola, Kayhty (bib0100) 1999; 118 Flannery, Heffernan, Harrison, Ray, Reingold, Hadler (bib0010) 2006; 144 Spoulou, Tsoumas, Papaevangelou, Mostrou, Theodoridou (bib0120) 2003; 17 McVernon, Johnson, Pollard, Slack, Moxon (bib0080) 2003; 88 French, Gordon, Mwalukomo, White, Mwafulirwa, Longwe (bib0030) 2010; 362 Tarrago, Casal, Ruiz-Contreras, Ramos, Rojo, Snippe (bib0070) 2005; 12 Usinger, Lucas (bib0095) 1999; 67 Klugman, Madhi, Adegbola, Cutts, Greenwood, Hausdorff (bib0055) 2011; 29 Feikin, Elie, Goetz, Lennox, Carlone, Romero-Steiner (bib0115) 2002; 20 Abzug, Qin, Levin, Fenton, Beeler, Bellini (bib0050) 2012; 206 Madhi, Kuwanda, Cutland, Holm, Käyhty, Klugman (bib0075) 2005; 24 Madhi, Klugman, Kuwanda, Cutland, Käyhty, Quantitative (bib0025) 2009; 199 Abzug, Pelton (bib0005) 2009; 199 Wuorimaa, Dagan, Väkeväinen, Bailleux, Haikala, Yaich (bib0060) 2001; 184 Thanee, Pancharoen, Likitnukul, Luangwedchakarn, Umrod, Phasomsap (bib0105) 2011; 29 Abzug, Warshaw, Rosenblatt, Levin, Nachman, Pelton (bib0045) 2009; 200 Madhi, Adrian, Kuwanda, Jassat, Jones, Little (bib0035) 2007; 25 Abzug, Pelton, Song, Fenton, Levin, Nachman (bib0040) 2006; 25 Bliss, O’Brien, Janoff, Cotton, Musoke, Coovadia (bib0130) 2007; 8 (bib0065) 2009 Blanchard Rohner, Snape, Kelly, John, Morant, Yu (bib0085) 2008; 180 Madhi (10.1016/j.vaccine.2013.08.002_bib0155) 2010; 202 Madhi (10.1016/j.vaccine.2013.08.002_bib0025) 2009; 199 Abzug (10.1016/j.vaccine.2013.08.002_bib0040) 2006; 25 D’Orsogna (10.1016/j.vaccine.2013.08.002_bib0145) 2007; 21 Blanchard Rohner (10.1016/j.vaccine.2013.08.002_bib0085) 2008; 180 (10.1016/j.vaccine.2013.08.002_bib0065) 2009 Nunes (10.1016/j.vaccine.2013.08.002_bib0020) 2011; 25 Abzug (10.1016/j.vaccine.2013.08.002_bib0045) 2009; 200 Titanji (10.1016/j.vaccine.2013.08.002_bib0140) 2006; 108 Antttila (10.1016/j.vaccine.2013.08.002_bib0100) 1999; 118 Albrich (10.1016/j.vaccine.2013.08.002_bib0015) 2007; 44 Thanee (10.1016/j.vaccine.2013.08.002_bib0105) 2011; 29 Wuorimaa (10.1016/j.vaccine.2013.08.002_bib0060) 2001; 184 Madhi (10.1016/j.vaccine.2013.08.002_bib0075) 2005; 24 Abzug (10.1016/j.vaccine.2013.08.002_bib0050) 2012; 206 Tarrago (10.1016/j.vaccine.2013.08.002_bib0070) 2005; 12 Spoulou (10.1016/j.vaccine.2013.08.002_bib0110) 2005; 23 Feikin (10.1016/j.vaccine.2013.08.002_bib0115) 2002; 20 Abzug (10.1016/j.vaccine.2013.08.002_bib0005) 2009; 199 French (10.1016/j.vaccine.2013.08.002_bib0030) 2010; 362 McVernon (10.1016/j.vaccine.2013.08.002_bib0080) 2003; 88 Klugman (10.1016/j.vaccine.2013.08.002_bib0055) 2011; 29 Bliss (10.1016/j.vaccine.2013.08.002_bib0130) 2007; 8 Usinger (10.1016/j.vaccine.2013.08.002_bib0095) 1999; 67 Spoulou (10.1016/j.vaccine.2013.08.002_bib0120) 2003; 17 Madhi (10.1016/j.vaccine.2013.08.002_bib0035) 2007; 25 Iwajomo (10.1016/j.vaccine.2013.08.002_bib0150) 2011; 204 Hart (10.1016/j.vaccine.2013.08.002_bib0135) 2007; 178 Flannery (10.1016/j.vaccine.2013.08.002_bib0010) 2006; 144 Rutstein (10.1016/j.vaccine.2013.08.002_bib0125) 1996; 150 O’Brien (10.1016/j.vaccine.2013.08.002_bib0090) 2007; 7 |
| References_xml | – volume: 144 start-page: 1 year: 2006 end-page: 9 ident: bib0010 article-title: Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization publication-title: Annals of Internal Medicine – volume: 29 start-page: 5886 year: 2011 end-page: 5891 ident: bib0105 article-title: The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children publication-title: Vaccine – volume: 25 start-page: 920 year: 2006 end-page: 929 ident: bib0040 article-title: Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy publication-title: Pediatric Infectious Disease Journal – volume: 25 start-page: 2451 year: 2007 end-page: 2457 ident: bib0035 article-title: Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine publication-title: Vaccine – volume: 88 start-page: 379 year: 2003 end-page: 383 ident: bib0080 article-title: Immunologic memory in publication-title: Archives of Disease in Childhood – volume: 29 start-page: 3372 year: 2011 end-page: 3373 ident: bib0055 article-title: Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose publication-title: Vaccine – volume: 118 start-page: 402 year: 1999 end-page: 407 ident: bib0100 article-title: Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against publication-title: Clinical and Experimental Immunology – volume: 20 start-page: 545 year: 2002 end-page: 553 ident: bib0115 article-title: Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults publication-title: Vaccine – volume: 199 start-page: 1168 year: 2009 end-page: 1176 ident: bib0025 article-title: qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination publication-title: Journal of Infectious Diseases – volume: 202 start-page: 355 year: 2010 end-page: 361 ident: bib0155 article-title: Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants publication-title: Journal of Infectious Diseases – year: 2009 ident: bib0065 article-title: Recommendations to assure the quality, safety, and efficacy of pneumococcal conjugate vaccines publication-title: 60th Meeting of the WHO Expert Committee on Biological Standardization – volume: 108 start-page: 1580 year: 2006 end-page: 1587 ident: bib0140 article-title: Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection publication-title: Blood – volume: 206 start-page: 512 year: 2012 end-page: 522 ident: bib0050 article-title: Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy publication-title: J Infect Dis – volume: 184 start-page: 1211 year: 2001 end-page: 1215 ident: bib0060 article-title: Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant publication-title: J. Infect. Dis. – volume: 204 start-page: 534 year: 2011 end-page: 543 ident: bib0150 article-title: Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV infection publication-title: Journal of Infectious Diseases – volume: 23 start-page: 5289 year: 2005 end-page: 5293 ident: bib0110 article-title: Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children publication-title: Vaccine – volume: 150 start-page: 838 year: 1996 end-page: 842 ident: bib0125 article-title: Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenza type b conjugate vaccine publication-title: Archives of Pediatrics & Adolescent Medicine – volume: 25 start-page: 453 year: 2011 end-page: 462 ident: bib0020 article-title: The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis publication-title: AIDS – volume: 200 start-page: 935 year: 2009 end-page: 946 ident: bib0045 article-title: Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy publication-title: J Infect Dis – volume: 180 start-page: 2165 year: 2008 end-page: 2173 ident: bib0085 article-title: The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response publication-title: Journal of Immunology – volume: 21 start-page: 1747 year: 2007 end-page: 1752 ident: bib0145 article-title: Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy publication-title: AIDS – volume: 178 start-page: 8212 year: 2007 end-page: 8220 ident: bib0135 article-title: Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease publication-title: Journal of Immunology – volume: 17 start-page: 1396 year: 2003 end-page: 1398 ident: bib0120 article-title: Haemophilus influenza type b conjugate vaccine-induced immunological memory in symptomatic HIV-1-infected children publication-title: AIDS – volume: 67 start-page: 2366 year: 1999 end-page: 2370 ident: bib0095 article-title: Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides publication-title: Infection and Immunity – volume: 199 start-page: 1109 year: 2009 end-page: 1111 ident: bib0005 article-title: Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox publication-title: Journal of Infectious Diseases – volume: 8 start-page: 67 year: 2007 end-page: 80 ident: bib0130 article-title: The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease publication-title: Lancet Infectious Diseases – volume: 362 start-page: 812 year: 2010 end-page: 822 ident: bib0030 article-title: A trial of 7-valent pneumococcal conjugate vaccine in HIV-infected adults publication-title: New England Journal of Medicine – volume: 12 start-page: 165 year: 2005 end-page: 170 ident: bib0070 article-title: Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection publication-title: Clinical and Diagnostic Laboratory Immunology – volume: 24 start-page: 410 year: 2005 end-page: 416 ident: bib0075 article-title: Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children publication-title: Pediatric Infectious Disease Journal – volume: 44 start-page: 1569 year: 2007 end-page: 1576 ident: bib0015 article-title: Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine publication-title: Clinical Infectious Diseases – volume: 7 start-page: 597 year: 2007 end-page: 606 ident: bib0090 article-title: Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue publication-title: Lancet Infectious Diseases – volume: 44 start-page: 1569 year: 2007 ident: 10.1016/j.vaccine.2013.08.002_bib0015 article-title: Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine publication-title: Clinical Infectious Diseases doi: 10.1086/518149 – volume: 8 start-page: 67 year: 2007 ident: 10.1016/j.vaccine.2013.08.002_bib0130 article-title: The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease publication-title: Lancet Infectious Diseases doi: 10.1016/S1473-3099(07)70242-6 – volume: 17 start-page: 1396 year: 2003 ident: 10.1016/j.vaccine.2013.08.002_bib0120 article-title: Haemophilus influenza type b conjugate vaccine-induced immunological memory in symptomatic HIV-1-infected children publication-title: AIDS doi: 10.1097/00002030-200306130-00017 – volume: 178 start-page: 8212 year: 2007 ident: 10.1016/j.vaccine.2013.08.002_bib0135 article-title: Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease publication-title: Journal of Immunology doi: 10.4049/jimmunol.178.12.8212 – volume: 25 start-page: 920 year: 2006 ident: 10.1016/j.vaccine.2013.08.002_bib0040 article-title: Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy publication-title: Pediatric Infectious Disease Journal doi: 10.1097/01.inf.0000237830.33228.c3 – volume: 108 start-page: 1580 year: 2006 ident: 10.1016/j.vaccine.2013.08.002_bib0140 article-title: Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection publication-title: Blood doi: 10.1182/blood-2005-11-013383 – volume: 29 start-page: 5886 year: 2011 ident: 10.1016/j.vaccine.2013.08.002_bib0105 article-title: The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children publication-title: Vaccine doi: 10.1016/j.vaccine.2011.06.072 – volume: 362 start-page: 812 year: 2010 ident: 10.1016/j.vaccine.2013.08.002_bib0030 article-title: A trial of 7-valent pneumococcal conjugate vaccine in HIV-infected adults publication-title: New England Journal of Medicine doi: 10.1056/NEJMoa0903029 – volume: 12 start-page: 165 year: 2005 ident: 10.1016/j.vaccine.2013.08.002_bib0070 article-title: Assessment of antibody response elicited by a 7-valent pneumococcal conjugate vaccine in pediatric human immunodeficiency virus infection publication-title: Clinical and Diagnostic Laboratory Immunology doi: 10.1128/CDLI.12.1.165-170.2005 – volume: 184 start-page: 1211 year: 2001 ident: 10.1016/j.vaccine.2013.08.002_bib0060 article-title: Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant publication-title: J. Infect. Dis. doi: 10.1086/323648 – volume: 180 start-page: 2165 year: 2008 ident: 10.1016/j.vaccine.2013.08.002_bib0085 article-title: The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response publication-title: Journal of Immunology doi: 10.4049/jimmunol.180.4.2165 – volume: 25 start-page: 453 year: 2011 ident: 10.1016/j.vaccine.2013.08.002_bib0020 article-title: The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis publication-title: AIDS doi: 10.1097/QAD.0b013e328341b7f1 – volume: 25 start-page: 2451 year: 2007 ident: 10.1016/j.vaccine.2013.08.002_bib0035 article-title: Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine publication-title: Vaccine doi: 10.1016/j.vaccine.2006.09.019 – year: 2009 ident: 10.1016/j.vaccine.2013.08.002_bib0065 article-title: Recommendations to assure the quality, safety, and efficacy of pneumococcal conjugate vaccines – volume: 118 start-page: 402 year: 1999 ident: 10.1016/j.vaccine.2013.08.002_bib0100 article-title: Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae publication-title: Clinical and Experimental Immunology doi: 10.1046/j.1365-2249.1999.01077.x – volume: 21 start-page: 1747 year: 2007 ident: 10.1016/j.vaccine.2013.08.002_bib0145 article-title: Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy publication-title: AIDS doi: 10.1097/QAD.0b013e32828642c7 – volume: 29 start-page: 3372 year: 2011 ident: 10.1016/j.vaccine.2013.08.002_bib0055 article-title: Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose publication-title: Vaccine doi: 10.1016/j.vaccine.2011.02.089 – volume: 199 start-page: 1168 year: 2009 ident: 10.1016/j.vaccine.2013.08.002_bib0025 article-title: qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination publication-title: Journal of Infectious Diseases doi: 10.1086/597388 – volume: 206 start-page: 512 year: 2012 ident: 10.1016/j.vaccine.2013.08.002_bib0050 article-title: Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy publication-title: J Infect Dis doi: 10.1093/infdis/jis386 – volume: 67 start-page: 2366 year: 1999 ident: 10.1016/j.vaccine.2013.08.002_bib0095 article-title: Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides publication-title: Infection and Immunity doi: 10.1128/IAI.67.5.2366-2370.1999 – volume: 199 start-page: 1109 year: 2009 ident: 10.1016/j.vaccine.2013.08.002_bib0005 article-title: Prevention of invasive pneumococcal disease in HIV-infected children: expanding the toolbox publication-title: Journal of Infectious Diseases doi: 10.1086/597389 – volume: 20 start-page: 545 year: 2002 ident: 10.1016/j.vaccine.2013.08.002_bib0115 article-title: Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults publication-title: Vaccine doi: 10.1016/S0264-410X(01)00347-4 – volume: 202 start-page: 355 year: 2010 ident: 10.1016/j.vaccine.2013.08.002_bib0155 article-title: Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants publication-title: Journal of Infectious Diseases doi: 10.1086/653704 – volume: 23 start-page: 5289 year: 2005 ident: 10.1016/j.vaccine.2013.08.002_bib0110 article-title: Immunogenicity and immunological memory induced by a 7-valent pneumococcal CRM197 conjugate vaccine in symptomatic HIV-1 infected children publication-title: Vaccine doi: 10.1016/j.vaccine.2005.06.002 – volume: 88 start-page: 379 year: 2003 ident: 10.1016/j.vaccine.2013.08.002_bib0080 article-title: Immunologic memory in Haemophilus influenzae type b conjugate vaccine failure publication-title: Archives of Disease in Childhood doi: 10.1136/adc.88.5.379 – volume: 7 start-page: 597 year: 2007 ident: 10.1016/j.vaccine.2013.08.002_bib0090 article-title: Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue publication-title: Lancet Infectious Diseases doi: 10.1016/S1473-3099(07)70210-4 – volume: 24 start-page: 410 year: 2005 ident: 10.1016/j.vaccine.2013.08.002_bib0075 article-title: Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children publication-title: Pediatric Infectious Disease Journal doi: 10.1097/01.inf.0000160942.84169.14 – volume: 204 start-page: 534 year: 2011 ident: 10.1016/j.vaccine.2013.08.002_bib0150 article-title: Deteriorating pneumococcal-specific B-cell memory in minimally symptomatic African children with HIV infection publication-title: Journal of Infectious Diseases doi: 10.1093/infdis/jir316 – volume: 144 start-page: 1 year: 2006 ident: 10.1016/j.vaccine.2013.08.002_bib0010 article-title: Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization publication-title: Annals of Internal Medicine doi: 10.7326/0003-4819-144-1-200601030-00004 – volume: 150 start-page: 838 year: 1996 ident: 10.1016/j.vaccine.2013.08.002_bib0125 article-title: Response of human immunodeficiency virus-exposed and -infected infants to Haemophilus influenza type b conjugate vaccine publication-title: Archives of Pediatrics & Adolescent Medicine doi: 10.1001/archpedi.1996.02170330064011 – volume: 200 start-page: 935 year: 2009 ident: 10.1016/j.vaccine.2013.08.002_bib0045 article-title: Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy publication-title: J Infect Dis doi: 10.1086/605448 |
| SSID | ssj0005319 |
| Score | 2.1950235 |
| Snippet | •HIV-infected children were studied following pneumococcal vaccination on HAART.•Subjects received 2 conjugate (PCV) and 1 polysaccharide (PPV) vaccine... Highlights • HIV-infected children were studied following pneumococcal vaccination on HAART. • Subjects received 2 conjugate (PCV) and 1 polysaccharide (PPV)... BACKGROUND: The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. METHODS: HIV-infected... The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. HIV-infected children 2-<19 years... Background The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. Methods HIV-infected children... The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection.BACKGROUNDThe capacity of pneumococcal... Background: The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. Methods: HIV-infected... Background: The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection. The capacity of pneumococcal vaccination to confer memory in HIV-infected children is critical for durable protection.HIV-infected children 2–<19 years... |
| SourceID | pubmedcentral proquest pubmed pascalfrancis crossref fao elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4782 |
| SubjectTerms | Adolescent Allergy and Immunology antibodies Antibodies, Bacterial - blood Antibody Affinity Antiretroviral agents Antiretroviral drugs Antiretroviral Therapy, Highly Active Applied microbiology Bacteriology Biological and medical sciences Child Children Children & youth clinical trials Drug therapy Enzyme-Linked Immunosorbent Assay Female Fundamental and applied biological sciences. Psychology HIV HIV infections HIV Infections - drug therapy HIV Infections - immunology Human immunodeficiency virus Human viral diseases Humans Immunization Immunologic Memory Infectious diseases Male Medical sciences Memory Microbiology Miscellaneous Pneumococcal Pneumococcal Infections - immunology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - immunology serotypes Streptococcus pneumoniae vaccination Vaccination - methods Vaccine Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids viral load Young Adult |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLbYEIgXBOWywJiMhPa0dE7s3J7QhJgK0tCkrVPfLMdJRqsuKSRFyu_iD3JOnAtFW0df7dPEJ8efP9vnQsgH5sYc1x07wbAesBDHVjrQNtOahylCpsZo5LNv_mQqvs68WXvgVrZulR0mNkCdFBrPyI_x-gy2IsLzPq5-2Fg1Cm9X2xIaO-Rhk7oM7DmYBYOLB28Ke8A2Q9jCYbMhgud4Mf6lNF5do3cXHxuPyrvWpp1MFeg0qUrQW2YKXtzGSP91rPxrpTp9Rp62FJOeGJt4Th6k-Yg8MkUn6xF5fNZep4_I4blJXF0f0cshDqs8oof0fEhpDTKjK_SaaUJ3aSf-gvw-yat5XCQ1XeGpW9nQb6ryhM4x6sTAKr1BX96aNsXIqfHcBlRZ0lWerm8KwGMYLYVd-WKNJ3qN-KpY1iUoDt5hnqTU6LAxITrP6eTLlW18yNKEdsHoFNow9fISntRAOPxRBXBe4ZEJKImaQLP6JZmefr78NLHbIhC2DrygsqMwE67WYaKV9kWsgYBmIWzDWBylmFhGhxlToRBBwBKPacE0z5xYKKAyigepx1-R3bzI0z1CHRXEGWcJ1zxFr4LYyVSofEcL2BMqzSwius8vdZshHQt1LGXnCreQrdVItBqJBTyZa5FxL7YyKULuE_A725Jd_CsgtoRF7D7B4DbBtGxxp5SOLF3J5AVreC6bAUPBUlrCImEv2VIrQ5n-56F7YP5SXcOiI6cXLh6RIYwzEVjkYGNO9MN3A5iMzI0sst9NEjm8Yz-TLfK-bwZUw6sqlafFGvoIzoFpc-Fu6-OH3HfCKNrSx0MOHIX4rnf28THHI-YwtchrM3-HgXAYCJBa0PzGzO47YHb2zZZ8_r3J0g4Q6MHvzXYVvCVPUNfGPXSf7FY_1-k7oLlVfNBg2R9fpaqF priority: 102 providerName: ProQuest |
| Title | Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0264410X13010864 https://www.clinicalkey.es/playcontent/1-s2.0-S0264410X13010864 https://dx.doi.org/10.1016/j.vaccine.2013.08.002 https://www.ncbi.nlm.nih.gov/pubmed/23954381 https://www.proquest.com/docview/1559094455 https://www.proquest.com/docview/1433515342 https://www.proquest.com/docview/1468361899 https://www.proquest.com/docview/1500789847 https://www.proquest.com/docview/1686710313 https://pubmed.ncbi.nlm.nih.gov/PMC3825555 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZ2EYgXBOWywJiMhPa0tE7s3B7HtKkDbarYOvXNcpxkpOqSirRIfeFP8Qc5J05aCrsg-pBe4tPEJ_bnY_s75xDygbkxx3HHTtCtB1qIYysdaJtpzcMUIVOjN_LZud8fik8jb7RBjlpfGKRVNthvML1G6-aXXqPN3jTPexesHsvZCFAY0wWJTbLt8sj3tsj24enn_vmK6cHr_B5Y3kaBlSNPb9z9rjTuYCPJi3cNsfKuIWozUyVyJ1UF6stM3ovbDNM_-ZW_DVgnz8jTxtKkh6Yyz8lGWnTII5N7ctEhj8-aXfUO2R-Y-NWLA3q5cseqDug-HawiW4NM5wrJM7UHL23FX5Cfh8Usj8tkQae4-FbVVjhVRUJzdD4x6EpvkNK7oHVOcmoI3AAuEzot0vlNCbAMtaUwOR_PcWGvFp-Wk0UFioN7yJOUGh3WLYnmBe2fXtmGSpYmtPVJp3AOIzBP4Eo1ksMfzeAJz3DlBJREjb_Z4iUZnhxfHvXtJheErQMvmNlRmAlX6zDRSvsi1mCHZiHMxlgcpRhfRocZU6EQQcASj2nBNM-cWCiwaBQPUo-_IltFWaQ7hDoqiDPOEq55iuSC2MlUqHxHC5gaKs0sItrHL3UTKB3zdUxky4gby6bVSGw1EvN4Mtci3aXY1EQKeUjAb9uWbN1gAbgljGUPCQa3CaZVAz-VdGTlSib_6iIWCZeSa73sXy66A81fqmsYe-TwwsWVMkRzJgKL7K31iWX13SCCCYEbWWS37SRydY8wl2WREJ5nkffL0wBuuGOlirScQxnBORjcXLj3lfFD7jthFN1TxkNTOArxXu8s42OoRwxlapHXpv-uKsKhImDbgubXevayAAZpXz9T5F_rYO2AhB683vy_5t-SJ_jNMEh3ydbs2zx9B5bwLN4jm90fDhyDUQDH8Ag-G-yD94_H54MvvwAfE7o- |
| linkProvider | Elsevier |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKKx4XBAulgVKMBD01rRM7rwNCBVpt6UMV7VZ7M46TwFbbZCG7oPwpLvxBZuJkl6I-uHSv8Wxiezzz2f5mhpBXzI05-h07wbAe0BDHVjrQNtOahymaTI3RyPsHfrcnPva9_hz51cbCIK2ytYm1oU4KjWfkG3h9BlsR4XlvR99srBqFt6ttCQ2jFrtp9RO2bOWbnQ8wv69dd3vr-H3XbqoK2DrwgrEdhZlwtQ4TrbQvYg2IJgsB17M4SjFTiQ4zpkIhgoAlHtOCaZ45sVDgGxUPUqwSASZ_QWBE6zxZeLd1cPhpRirhdSkR2NgIWzisP4sZ2jhd_6E0XpYjn4yvGw7nZd7wVqYKpGmqEmYqMyU2LsLA_1I5__KN2w_I_QbU0k2jhQ_JXJp3yG1T5rLqkDv7zQV-h6wemlTZ1Ro9nkV-lWt0lR7OkmiDTOcEeTp1sDBtxR-R35v5eBAXSUVHeM5X1oCfqjyhA4xzMYacniF7uKJ1-XNquOJgx4Z0lKeTswI8APSW6iI_neAZYi0-KoZVCQMH3zBIUmrGsFZaOshpd-fENqy1NKFt-DuFZ5jseQhvqp0G_NEYHMgYD2lgkKgJbasek96NKMgimc-LPF0i1FFBnHGWcM1T5DHETqZC5TtawC5UaWYR0U6_1E1OdiwNMpQt-e5UNlojUWsklgxlrkXWp2Ijk5TkOgG_1S3ZRtyCj5DgNq8TDC4STMvG0pXSkaUrmTxiNbJmfcBEWLxLWCScSjZgzoC0_3npEqi_VF_AzcnekYuHcug4mAgssnJuTUy77wYR7D3cyCLL7SKRs2-c2g6LvJw-BjuKl2MqT4sJtBGcA7bnwr2qjR9y3wmj6Io2HqLuKMRvvbSNj1klMWuqRZ6Y9TvrCIeOAIyGkT-3sqcNMB_8-Sf54GudFx6Mrge_p1cPwQtyt3u8vyf3dg52n5F7OO6GnLpM5sffJ-lzANnjeKWxbJR8vmlj-geII-hM |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKERUXBMujgVKMBD01rRM7cXJAqKJULaVVpT60N9dxEthqmyxkF5TfxY1fx0yc7FLUB5fuNZ5NbI9nPtvfzBDyhvkJR7_jphjWAxriudpI4zJjeJShyTQYjby3H24fi0_9oD9HfnexMEir7GxiY6jT0uAZ-Tpen8FWRATBet7SIg42t96PvrlYQQpvWrtyGlZFdrP6J2zfqnc7mzDXb31_6-PRh223rTDgGhnIsRtHufCNiVKjTSgSA-gmjwDjsyTOMGuJiXKmIyGkZGnAjGCG514iNPhJzWWGFSPA_N-VHFAVrCXZlzN6CW-KisAWR7jCY_1Z9ND62doPbfDaHJllfM2yOa_yi3dyXSJhU1cwZ7kttnEZGv6X1PmXl9x6SB608JZuWH18ROayokfu2YKXdY8s7LVX-T2ycmCTZter9GgWA1at0hV6MEunDTK9E2TsNGHDtBN_TH5tFONBUqY1HeGJX9VAf6qLlA4w4sWadHqOPOKaNoXQqWWNg0Ub0lGRTc5L8AXQW2rK4myCp4mN-Kgc1hUMHHzDIM2oHcNGfemgoNs7J67lr2Up7QLhKTzDtM9DeFPjPuCPxuBKxnhcA4NEbZBb_YQc34p6PCXzRVlki4R6WiY5Zyk3PENGQ-LlOtKhZwTsR7VhDhHd9CvTZmfHIiFD1dHwzlSrNQq1RmHxUOY7ZG0qNrLpSW4SCDvdUl3sLXgLBQ70JkF5mWBWtTavUp6qfMXUIWswNusDOsIyXsIh0VSyhXUWrv3PSxdB_ZX-Ag5PHR_6eDyHLoQJ6ZDlC2ti2n1fxrAL8WOHLHWLRM2-cWpFHPJ6-hgsKl6T6SIrJ9BGcA4onwv_ujZhxEMviuNr2gSIv-MIv_XKNiHml8T8qQ55ZtfvrCMcOgKAGkb-wsqeNsDM8BefFIOvTYZ4ML8B_J5fPwSvyAKYUPV5Z3_3BbmPw25Zqktkfvx9kr0EtD1OlhuzRsnpbdvRPy_R6xM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibody+persistence+and+immunologic+memory+after+sequential+pneumococcal+conjugate+and+polysaccharide+vaccination+in+HIV-infected+children+on+highly+active+antiretroviral+therapy&rft.jtitle=Vaccine&rft.au=Abzug%2C+MJ&rft.au=Song%2C+L+Y&rft.au=Levin%2C+MJ&rft.au=Nachman%2C+SA&rft.date=2013-10-01&rft.issn=0264-410X&rft.volume=31&rft.issue=42&rft.spage=4782&rft.epage=4790&rft_id=info:doi/10.1016%2Fj.vaccine.2013.08.002&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F0264410X%2FS0264410X13X00453%2Fcov150h.gif |